BIOMAT Database Logo BIOMAT Database Logo

Risk factors for CD4 lymphopenia in patients treated with a tenofovir/didanosine high dose-containing highly active antiretroviral therapy regimen. 2005

Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Assistance Publique, Hôpitaux de Paris, Hôpital Saint-Antoine, Service de Maladies Infectieuses et Tropicales, Paris F-75012, France.

In this study, the dynamics of CD4 cell depletion during tenofovir/didanosine co-administration were analysed. Ninety-five HIV-positive patients were followed for 562 days, and 37 lost at least 50 CD4 cells, with a median delay of 274 days. Cox analysis showed that the CD4 cell decrease was associated with a duration of treatment by didanosine of more than 853 days and a didanosine dose of more than 5.50 mg/kg.

UI MeSH Term Description Entries
D008231 Lymphopenia Reduction in the number of lymphocytes. Lymphocytopenia,Lymphocytopenias,Lymphopenias
D008297 Male Males
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000068698 Tenofovir An adenine analog REVERSE TRANSCRIPTASE INHIBITOR with antiviral activity against HIV-1 and HEPATITIS B. It is used to treat HIV INFECTIONS and CHRONIC HEPATITIS B, in combination with other ANTIVIRAL AGENTS, due to the emergence of ANTIVIRAL DRUG RESISTANCE when it is used alone. (R)-9-(2-phosphonylmethoxypropyl)adenine,9-(2-Phosphonomethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine,9-(2-Phosphonylmethoxypropyl)adenine, (+-)-isomer,9-(2-Phosphonylmethoxypropyl)adenine, (R)-isomer - T357098,9-(2-Phosphonylmethoxypropyl)adenine, (S)-isomer,9-PMPA (tenofovir),Tenofovir Disoproxil,Tenofovir Disoproxil Fumarate,Viread,Disoproxil Fumarate, Tenofovir,Disoproxil, Tenofovir,Fumarate, Tenofovir Disoproxil
D000225 Adenine A purine base and a fundamental unit of ADENINE NUCLEOTIDES. Vitamin B 4,4, Vitamin B,B 4, Vitamin
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults
D012307 Risk Factors An aspect of personal behavior or lifestyle, environmental exposure, inborn or inherited characteristic, which, based on epidemiological evidence, is known to be associated with a health-related condition considered important to prevent. Health Correlates,Risk Factor Scores,Risk Scores,Social Risk Factors,Population at Risk,Populations at Risk,Correlates, Health,Factor, Risk,Factor, Social Risk,Factors, Social Risk,Risk Factor,Risk Factor Score,Risk Factor, Social,Risk Factors, Social,Risk Score,Score, Risk,Score, Risk Factor,Social Risk Factor
D015496 CD4-Positive T-Lymphocytes A critical subpopulation of T-lymphocytes involved in the induction of most immunological functions. The HIV virus has selective tropism for the T4 cell which expresses the CD4 phenotypic marker, a receptor for HIV. In fact, the key element in the profound immunosuppression seen in HIV infection is the depletion of this subset of T-lymphocytes. T4 Cells,T4 Lymphocytes,CD4-Positive Lymphocytes,CD4 Positive T Lymphocytes,CD4-Positive Lymphocyte,CD4-Positive T-Lymphocyte,Lymphocyte, CD4-Positive,Lymphocytes, CD4-Positive,T-Lymphocyte, CD4-Positive,T-Lymphocytes, CD4-Positive,T4 Cell,T4 Lymphocyte
D015658 HIV Infections Includes the spectrum of human immunodeficiency virus infections that range from asymptomatic seropositivity, thru AIDS-related complex (ARC), to acquired immunodeficiency syndrome (AIDS). HTLV-III Infections,HTLV-III-LAV Infections,T-Lymphotropic Virus Type III Infections, Human,HIV Coinfection,Coinfection, HIV,Coinfections, HIV,HIV Coinfections,HIV Infection,HTLV III Infections,HTLV III LAV Infections,HTLV-III Infection,HTLV-III-LAV Infection,Infection, HIV,Infection, HTLV-III,Infection, HTLV-III-LAV,Infections, HIV,Infections, HTLV-III,Infections, HTLV-III-LAV,T Lymphotropic Virus Type III Infections, Human

Related Publications

Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Risk factors for hepatotoxicity in patients treated with highly active antiretroviral therapy.
July 2001, Journal of acquired immune deficiency syndromes (1999),
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Characteristics of foot fractures in HIV-infected patients previously treated with tenofovir versus non-tenofovir-containing highly active antiretroviral therapy.
January 2011, HIV/AIDS (Auckland, N.Z.),
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Semen quality and drug concentrations in seminal plasma of patients using a didanosine or didanosine plus tenofovir containing antiretroviral regimen.
October 2007, Therapeutic drug monitoring,
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Pancreatitis in an HIV-infected person on a tenofovir, didanosine and stavudine containing highly active antiretroviral treatment.
August 2003, The Journal of infection,
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
High rate of virological failure in maintenance antiretroviral therapy with didanosine and tenofovir.
October 2005, AIDS (London, England),
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Cerebrovascular disease in highly active antiretroviral therapy-treated individuals: incidence and risk factors.
January 2005, Journal of neurovirology,
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
High rate of K65R for antiretroviral therapy-naive patients with subtype C HIV infection failing a tenofovir-containing first-line regimen.
August 2012, AIDS (London, England),
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Fatal lactic acidosis and acute renal failure after addition of tenofovir to an antiretroviral regimen containing didanosine.
April 2003, Clinical infectious diseases : an official publication of the Infectious Diseases Society of America,
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Hypofibrinolytic state in HIV-1-infected patients treated with protease inhibitor-containing highly active antiretroviral therapy.
April 2002, Journal of acquired immune deficiency syndromes (1999),
Karine Lacombe, and Jérôme Pacanowski, and Jean-Luc Meynard, and Aldo Trylesinski, and Pierre-Marie Girard
Homocysteinaemia in HIV-infected patients treated with highly active antiretroviral therapy.
May 2001, AIDS (London, England),
Copied contents to your clipboard!